Lilly plans 2026 EHA presentation of early data for AJX-101, a type II JAK2 inhibitor in myelofibrosis

Eli Lilly is preparing to present early clinical data tied to its AJX-101 program, an investigational type II JAK2 inhibitor being studied in myelofibrosis. In an announcement posted Tuesday, the company said it expects to share “initial clinical data” at the 2026 annual meeting of the European Hematology Association (EHA), an industry gathering where late-stage and early-stage hematology trial updates are commonly showcased.

The targeted population in the company’s update is patients with previously treated myelofibrosis, a rare bone marrow disorder in which scar tissue can disrupt normal blood-cell production. In such cases, patients typically receive multiple lines of therapy over time, and treatment decisions often hinge on symptom burden, anemia-related outcomes, and markers of disease activity.

Lilly’s AJX-101 program centers on a compound identified in the announcement as AJ1-11095, described as a “type II” JAK2 inhibitor. JAK2 refers to Janus kinase 2, an enzyme that plays a role in indicating pathways implicated in myeloproliferative neoplasms. A type II inhibitor is designed to bind to a specific inactive configuration of its target, a design intended to influence potency and selectivity relative to older or “type I” approaches. The company did not provide additional mechanistic detail beyond that classification in its posted announcement.

According to the company, the Phase 1 AJX-101 study generated an “encouraging safety profile” and “promising” clinical indicates, which will be discussed in the EHA presentation. Lilly’s announcement did not specify the number of patients enrolled, the treatment dose levels, the duration of follow-up, or any quantified safety outcomes. It also did not disclose efficacy metrics such as response rates, duration of response, symptom-improvement rates, or biomarker changes in the post.

What Lilly did disclose is the nature of the data release: early findings from an ongoing Phase 1 trial focused on previously treated patients. In Phase 1 settings, safety is typically the primary focus, while efficacy observations are often preliminary and used to guide future dose selection and trial design. Lilly’s decision to highlight both safety and early efficacy suggests it believes the program is at a stage where the company can share enough information to inform the field ahead of later-phase development.

For myelofibrosis, the competitive landscape has been shaped in recent years by therapies aimed at controlling disease-driving indicating and alleviating symptoms. The next question for investors and clinicians is whether AJ1-11095 can show durability of benefit and a tolerable side-effect profile in a broader population, including patients who have already received prior therapies. Lilly’s update is a step in that direction, but without the trial’s numerical results it is not possible to assess how the outcomes compare with existing standards or with other investigational programs.

Still, Lilly’s planned EHA presentation matters because it will likely be one of the first public opportunities for the company to lay out more complete trial context, including patient characteristics and the shape of the safety and early efficacy dataset. Conference abstracts often provide a more detailed breakdown than corporate posts, and they can help clarify the magnitude of any observed activity and the specific adverse events seen at different dose levels.